Apimeds Pharmaceuticals US, Inc. (APUS) vs Sonoma Pharmaceuticals, Inc. (SNOA)
- Apimeds Pharmaceuticals US, Inc. APUS 4.04 −7.97%
- Sonoma Pharmaceuticals, Inc. SNOA 1.13 −1.74%
Apimeds Pharmaceuticals US, Inc. and Sonoma Pharmaceuticals, Inc. are both Drug Manufacturers Specialty & Generic companies. Apimeds Pharmaceuticals US, Inc. is the larger, with a market value of $6.6M against $5.5M — 1.2× the size. Apimeds Pharmaceuticals US, Inc. has the higher net margin (0.00% vs −10.3%) and the higher return on invested capital (−16.0% vs −70.0%). Across the 13 metrics below, Sonoma Pharmaceuticals, Inc. leads on 7 and Apimeds Pharmaceuticals US, Inc. on 6.
Valuation
Profitability
| Metric | APUS | SNOA | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | — | 38.91% | 53.94% |
| Operating margin | 0.00% | (6.41%) | 0.00% |
| Net margin | 0.00% | (10.33%) | 0.00% |
| Free cash flow margin | 0.00% | (12.11%) | 0.00% |
| Return on equity | (100.13%) | (42.52%) | (0.40%) |
| Return on assets | (84.20%) | (13.85%) | (3.32%) |
| Return on invested capital | (15.96%) | (69.96%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack